The Antipsychotic Load (AP_Load2026): a normalised prescribed-dose index for schizophrenia research
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background and Hypothesis Schizophrenia research routinely reduces antipsychotic treatment to a single number, but the available summaries disagree. Chlorpromazine equivalents, the WHO Defined Daily Dose (DDD) and the percentage of the licensed maximum (%BNFmax) rank the same patient differently, most of all for clozapine, whose dose-concentration relationship varies several-fold with sex and smoking. We hypothesised that referencing clozapine dose to a target individualised for sex and smoking would track plasma clozapine better than dose-proportional measures. Study Design In the Antipsychotic Load (AP_Load2026), each daily dose is expressed as a percentage of a reference dose, summed without a cap. Clozapine is referenced to a target individualised for sex and cigarettes per day, under two published anchor schemes, and other antipsychotics to a dose reconciling the WHO DDD and the licensed maximum. The clozapine term was tested against plasma clozapine (1316 assessments, 255 patients) with log-log mixed-effects models, and the non-clozapine reference against independently derived published doses. Study Results The individualised reference tracked plasma clozapine better than any dose-proportional measure (marginal R^2 0.249 vs. 0.166; deltaR^2 0.082, 95% CI 0.044-0.120). The scheme with the larger smoking correction fitted better (0.249 vs. 0.231), an ordering robust to quality-control variants and co-prescription. Of five candidate references for other antipsychotics, %BNFmax was the least consistent with external criteria. Conclusions AP_Load2026 is a transparent framework for normalising prescribed antipsychotic dose. Its clozapine reference is validated against a biomarker, whereas the reference for other antipsychotics is a calibrated convention at least comparable with existing alternatives. The index is particularly suited to treatment-resistant and clozapine-enriched cohorts.